{"log_id": 8011031796674908845, "direction": 0, "words_result_num": 30, "words_result": [{"probability": {"variance": 0.010288, "average": 0.952355, "min": 0.473482}, "location": {"width": 831, "top": 103, "height": 69, "left": 178}, "words": "基于PCWG2标准确定的至PSA进展时间:本品治疗组和安慰剂组受试者至PSA进展的中"}, {"probability": {"variance": 0.021539, "average": 0.911481, "min": 0.390275}, "location": {"width": 876, "top": 153, "height": 67, "left": 138}, "words": "位时间分别为111个月和5.6个月(HR=0.488:95%C1:[0.420;0.568p<0.01本品洽"}, {"probability": {"variance": 0.0167, "average": 0.931685, "min": 0.497671}, "location": {"width": 877, "top": 199, "height": 71, "left": 138}, "words": "疗维至PSA进展时间约为安慰剂级的两倍(HR=0.488,本品治疗组中出现经证实的PSA缓解"}, {"probability": {"variance": 0.009827, "average": 0.947045, "min": 0.437421}, "location": {"width": 851, "top": 249, "height": 68, "left": 143}, "words": "的受试者比例高于安慰剂组(62%V5.24%:p0001在有可测量的软组织病灶受试者中"}, {"probability": {"variance": 0.00241, "average": 0.979144, "min": 0.779103}, "location": {"width": 534, "top": 312, "height": 51, "left": 146}, "words": "本品治疗组观察到完全或部分缓解的受试者数量明显增加"}, {"probability": {"variance": 0.005529, "average": 0.978221, "min": 0.599869}, "location": {"width": 831, "top": 344, "height": 66, "left": 190}, "words": "至使用阿片类药物时间:最终分析时,本品治疗组和安慰剂组受试者至使用阿片类药物的"}, {"probability": {"variance": 0.030494, "average": 0.888224, "min": 0.373626}, "location": {"width": 821, "top": 395, "height": 62, "left": 148}, "words": "中位时间分别为33.4个月和234个月HR=0.72195%C0.614:0.846p<00001"}, {"probability": {"variance": 0.002336, "average": 0.982578, "min": 0.775905}, "location": {"width": 827, "top": 438, "height": 64, "left": 195}, "words": "至细胞毒性化疗开始的时间:本品治疗组和安慰剂组受试者至细胞毒性化疗开始的中位时"}, {"probability": {"variance": 0.014437, "average": 0.938355, "min": 0.422126}, "location": {"width": 631, "top": 496, "height": 53, "left": 152}, "words": "间分别为252个月和168个月(HR=0580:95%C:10.4870.691]"}, {"probability": {"variance": 0.010542, "average": 0.875038, "min": 0.684723}, "location": {"width": 61, "top": 495, "height": 21, "left": 849}, "words": "0001元"}, {"probability": {"variance": 0.012524, "average": 0.951057, "min": 0.458661}, "location": {"width": 832, "top": 530, "height": 65, "left": 197}, "words": "至ECOG体能状态评分恶化≥1分的时间:本品治疗组和安慰剂组受试者至ECOG体育状态"}, {"probability": {"variance": 0.013637, "average": 0.934272, "min": 0.561179}, "location": {"width": 872, "top": 579, "height": 62, "left": 156}, "words": "评分恶化≥1分的时间分别为12.3个月和10.9个月(HR=0821;95%CL[0.714:0.943],p=0.003。"}, {"probability": {"variance": 0.002043, "average": 0.985935, "min": 0.76955}, "location": {"width": 540, "top": 635, "height": 52, "left": 205}, "words": "下列研究终点体现了本品治疗具有统计学显著意义的优势:"}, {"probability": {"variance": 0.002606, "average": 0.981897, "min": 0.759798}, "location": {"width": 830, "top": 671, "height": 61, "left": 204}, "words": "客观缓解率:客观缓解率是指,有可测量病灶且按照 RECIST标准取得了完全或部分缓解的"}, {"probability": {"variance": 0.015346, "average": 0.948148, "min": 0.456639}, "location": {"width": 861, "top": 716, "height": 64, "left": 163}, "words": "受试者的比例(基线淋巴结大小需要≥2cm才能视为一个靶病灶)本品治疗组和安慰剂组中"}, {"probability": {"variance": 0.008289, "average": 0.959357, "min": 0.513269}, "location": {"width": 764, "top": 767, "height": 57, "left": 165}, "words": "在基线有可测量病灶且出现客观缓解的受试者比例分别为36%和16%(p<001)"}, {"probability": {"variance": 0.008629, "average": 0.961535, "min": 0.491828}, "location": {"width": 825, "top": 808, "height": 62, "left": 208}, "words": "疼痛:与安慰剂组相比,本品治疗组的平均疼痛强度进展风险显著降低18%(=0.0490)"}, {"probability": {"variance": 0.008426, "average": 0.958154, "min": 0.546596}, "location": {"width": 878, "top": 841, "height": 85, "left": 167}, "words": "本品治疗组和安慰剂组至疼痛强度进展的中位时间分别为267个月和184个月非医"}, {"probability": {"variance": 0.024021, "average": 0.918582, "min": 0.412809}, "location": {"width": 832, "top": 901, "height": 62, "left": 212}, "words": "至 fact-p毛总分)恶化的时间:与安慰剂组相比,本品治疗组的FCP(总分恶化风险"}, {"probability": {"variance": 0.024555, "average": 0.918824, "min": 0.410226}, "location": {"width": 877, "top": 948, "height": 62, "left": 171}, "words": "降低22%p=0.0028).本品治疗组和安慰剂组至 fact-p【总分)恶化的中位时间分别为127"}, {"probability": {"variance": 0.004467, "average": 0.966853, "min": 0.803713}, "location": {"width": 147, "top": 1019, "height": 35, "left": 175}, "words": "个月和83个月"}, {"probability": {"variance": 0.00466, "average": 0.969557, "min": 0.731241}, "location": {"width": 317, "top": 1107, "height": 37, "left": 179}, "words": "中国患者临床试验数据(研究3)"}, {"probability": {"variance": 0.019223, "average": 0.937383, "min": 0.433843}, "location": {"width": 572, "top": 1146, "height": 45, "left": 180}, "words": "未经化疗的转移性去势抵抗性前列腺癌意者( abi-prc3002)"}, {"probability": {"variance": 0.010734, "average": 0.966015, "min": 0.356163}, "location": {"width": 829, "top": 1174, "height": 54, "left": 224}, "words": "在位于亚洲(中国、马来西亚和泰国)和欧洲(俄罗斯)的42个研究中心进行的一项本"}, {"probability": {"variance": 0.007684, "average": 0.963567, "min": 0.618768}, "location": {"width": 947, "top": 1199, "height": 73, "left": 182}, "words": "联合泼尼松泼尼松龙《之后统称泼尼松)治疗无症状或有轻度症状的转移性去势抵抗性前列腺"}, {"probability": {"variance": 0.018929, "average": 0.949459, "min": 0.451234}, "location": {"width": 874, "top": 1260, "height": 54, "left": 183}, "words": "癌意者的随机、双盲、安慰剂对照的Ⅲ期临床研究中(研究3),受试者根据区域(亚洲或"}, {"probability": {"variance": 0.015566, "average": 0.932391, "min": 0.391638}, "location": {"width": 871, "top": 1306, "height": 49, "left": 185}, "words": "欧洲)和东部肿瘤协作组(ECOG)全身功能状态(PS评分(O或)分层,并随机分配(1:1"}, {"probability": {"variance": 0.007008, "average": 0.952808, "min": 0.576558}, "location": {"width": 872, "top": 1347, "height": 49, "left": 186}, "words": "接受本品联合泼尼松或安慰剂联合泼尼松。会格受试者空腹接受1000mg本品(以4x250mg片"}, {"probability": {"variance": 0.020503, "average": 0.9261, "min": 0.470566}, "location": {"width": 609, "top": 1397, "height": 41, "left": 188}, "words": "剂给药)或4.片安慰剂(每日1次)联合泼尼松5mg【每日2次"}, {"probability": {"variance": 0.000401, "average": 0.989593, "min": 0.882912}, "location": {"width": 830, "top": 1432, "height": 48, "left": 232}, "words": "本研究共入组313名受试者(157名受试者:本品联合泼尼松156名受试者:安慰剂联合"}], "language": 3}